Abstract:Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCCMubalake Abudoureyimu1, Yongting Lai2, Chuan Tian1, Ting Wang3, Rui Wang1* and Xiaoyuan Chu11 Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China2 Department of Medical Oncology, Jinling Hospital, Nanjing Clinical School of Southern Medical University, Nanjing, China3 Department of Medical Oncology, Jinling Hospital, Nanjing, China* Correspondence: Rui Wang, wangrui218@163.comKeywords: gene-targeted oncolytic viral therapy, adenovirus, HCC, immunotherapy, virus engineeringCorrigendum on: Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R and Chu X (2019) Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front. Oncol. 9:1182. doi: 10.3389/fonc.2019.01182 Missing FundingIn the original article, we neglected to include the funder **the Excellent Youth Foundation of Jiangsu Province, China**, **BK20140032** to **Rui Wang**. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Correction: ShRNA-Targeted COMMD7 Suppresses Hepatocellular Carcinoma Growth.

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Corrigendum to “circumventing Intratumoral Heterogeneity to Identify Potential Therapeutic Targets in Hepatocellular Carcinoma” [J Hepatol 67 (2017) 293–301]

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Corrigendum: Rational design of a Gd(III)–Cu(II) nanobooster for chemodynamic therapy against cancer cells

Corrigendum: Identification of novel therapeutic candidates against SARS-CoV-2 infections: An application of RNA sequencing toward mRNA based nanotherapeutics

Nanosonosensitizers for Highly Efficient Sonodynamic Cancer Theranostics: Erratum

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Corrigendum: Single-cell RNA sequencing reveals the role of phosphorylation-related genes in hepatocellular carcinoma stem cells

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy-an in vitro exploration